Stay updated on Duvelisib in Refractory Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.

Latest updates to the Duvelisib in Refractory Lymphoma Clinical Trial page
- Check6 days agoChange DetectedUpdated the study locations section to include detailed site locations by state/province and country (including Minsk Oblast, Ontario, and Quebec) and updated the revision to v3.3.3.SummaryDifference2%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedA note was added clarifying that PubMed publications are automatically populated and may not all relate to the study, and the revision label was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check35 days agoChange DetectedNotice about government funding status and NIH operating status has been removed from the page.SummaryDifference0.3%

- Check57 days agoChange DetectedNo substantive changes were detected in the Study Details page for NCT01882803; the core sections including eligibility criteria, primary outcomes, and locations appear unchanged between the screenshots.SummaryDifference0.3%

- Check78 days agoChange DetectedSignificant update: new operating-status notice and version bump to v3.2.0; previous v3.1.0 reference removed.SummaryDifference4%

- Check85 days agoChange DetectedUpdate: citation updated from v3.0.2 to v3.1.0 and addition of an erratum note; essentially a bibliographic metadata precision upgrade rather than a major content change.SummaryDifference0.5%

Stay in the know with updates to Duvelisib in Refractory Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.